Literature DB >> 26654934

Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.

Kelly Alanis-Hirsch1, Raina Croff2, James H Ford3, Kim Johnson4, Mady Chalk5, Laura Schmidt6, Dennis McCarty7.   

Abstract

The Medication Research Partnership (a national health plan and nine addiction treatment centers contracted with the health plan) sought to facilitate the adoption of pharmacotherapy for alcohol and opioid use disorders. Qualitative analysis of interviews with treatment center change leaders, individuals working for the manufacturer and its technical assistance contractor, and health plan managers extracted details on the processes used to order, store, bill for, and administer extended-release naltrexone. Qualitative themes were categorized using domains from the Consolidated Framework for Implementation Research (intervention characteristics, outer setting, inner setting, and provider characteristics). Characteristics of XR-NTX that inhibited use included the complexity of ordering and using the medication; cost was also a barrier. Outer setting barriers reflected patient needs and external health plan policies on formulary coverage, benefit management, and reimbursement. Program structures, the lack of physician linkages, a culture resistant to the use of medication, and unease with change were inner setting elements that limited use of XR-NTX. Patient stereotypes and a lack of knowledge about XR-NTX affected practitioner willingness to treat patients and prescribe XR-NTX. The Consolidated Framework for Implementation Research provided a useful lens to understand and interpret the processes affecting access to XR-NTX.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barriers; Consolidated framework for implementation research; Extended-release naltrexone; Naltrexone

Mesh:

Substances:

Year:  2015        PMID: 26654934      PMCID: PMC4724460          DOI: 10.1016/j.jsat.2015.10.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  18 in total

1.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

Review 2.  A guiding framework and approach for implementation research in substance use disorders treatment.

Authors:  Laura J Damschroder; Hildi J Hagedorn
Journal:  Psychol Addict Behav       Date:  2011-06

3.  Financial factors and the implementation of medications for treating opioid use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

4.  Extended-release naltrexone for treatment of alcohol dependence in primary care.

Authors:  Joshua D Lee; Ellie Grossman; Danae DiRocco; Andrea Truncali; Kathleen Hanley; David Stevens; John Rotrosen; Marc N Gourevitch
Journal:  J Subst Abuse Treat       Date:  2010-04-02

5.  Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach.

Authors:  John P Fitzgerald; Dennis McCarty
Journal:  Psychol Serv       Date:  2009-02-01

6.  Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.

Authors:  Amanda J Abraham; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2010-05       Impact factor: 2.582

7.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

8.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

9.  Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science.

Authors:  Laura J Damschroder; David C Aron; Rosalind E Keith; Susan R Kirsh; Jeffery A Alexander; Julie C Lowery
Journal:  Implement Sci       Date:  2009-08-07       Impact factor: 7.327

10.  The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.

Authors:  Sandra Lapham; Robert Forman; Mark Alexander; Ari Illeperuma; Michael J Bohn
Journal:  J Subst Abuse Treat       Date:  2008-09-04
View more
  25 in total

1.  Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Iuliia Makarenko; Alyona Mazhnaya; Alexei Zelenev; Maxim Polonsky; Lynn Madden; Sergii Filippovych; Sergii Dvoriak; Sandra A Springer; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2017-08-05       Impact factor: 4.492

2.  Overcoming Barriers to Adopting and Implementing Pharmacotherapy: the Medication Research Partnership.

Authors:  Raina Croff; Kim Hoffman; Kelly Alanis-Hirsch; Jay Ford; Dennis McCarty; Laura Schmidt
Journal:  J Behav Health Serv Res       Date:  2019-04       Impact factor: 1.505

3.  Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.

Authors:  Nora Jacobson; Julie Horst; Liam Wilcox-Warren; Alex Toy; Hannah K Knudsen; Randy Brown; Eric Haram; Lynn Madden; Todd Molfenter
Journal:  J Behav Health Serv Res       Date:  2020-10       Impact factor: 1.505

4.  Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV.

Authors:  Madeline C Frost; Theresa E Matson; Judith I Tsui; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2018-10-30       Impact factor: 4.492

5.  Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders.

Authors:  Hélène Chokron Garneau; Alexandra Venegas; Richard Rawson; Lara A Ray; Suzette Glasner
Journal:  J Subst Abuse Treat       Date:  2017-05-11

Review 6.  Update on Barriers to Pharmacotherapy for Opioid Use Disorders.

Authors:  Anjalee Sharma; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz
Journal:  Curr Psychiatry Rep       Date:  2017-06       Impact factor: 5.285

7.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

Review 8.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

9.  A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.

Authors:  Rebecca L Haffajee; Barbara Andraka-Christou; Jeremy Attermann; Anna Cupito; Jessica Buche; Angela J Beck
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-09-14

10.  Findings from the recovery initiation and management after overdose (RIMO) pilot study experiment.

Authors:  Christy K Scott; Michael L Dennis; Christine E Grella; Lisa Nicholson; Jamie Sumpter; Rachel Kurz; Rod Funk
Journal:  J Subst Abuse Treat       Date:  2019-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.